November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Curtis Lachowiez: Refining risk prediction for HMA and venetoclax-based treatment in AML
Nov 6, 2024, 16:47

Curtis Lachowiez: Refining risk prediction for HMA and venetoclax-based treatment in AML

Curtis Lachowiez, Assistant Professor of Medicine at Oregon Health and Science University, shared a post on X about his recent paper published in Blood Journal:

“Our manuscript refining risk prediction for HMA and venetoclax-based treatment in AML is now out in Blood Journal first edition!”

Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post, adding:

“Fantastic collaboration with Curtis Lachowiez, Daniel Pollyea and UK cohort refining risk stratification in patients treated with frontline Aza/Ven. All RAS mutations not created equal-KRAS and PTPN11 appear to be adverse risk compared to NRAS.”

“Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML”

Authors: Curtis Lachowiez, Vishvaas Ravikumar, Jad Othman, Joshua Zeidner, Daniel Pollyea et al.

Curtis Lachowiez: Refining risk prediction for HMA and venetoclax-based treatment in AML

More posts featuring Joshua Zeidner.

Curtis Lachowiez, MD, is an Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at Oregon Health and Science University, where he specializes in treating blood cancers, including myelodysplastic syndrome and acute myeloid leukemia. His research focuses on designing and implementing clinical trials to improve individualized therapies for leukemia and high-quality patient care.